JP2005508352A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005508352A5 JP2005508352A5 JP2003534405A JP2003534405A JP2005508352A5 JP 2005508352 A5 JP2005508352 A5 JP 2005508352A5 JP 2003534405 A JP2003534405 A JP 2003534405A JP 2003534405 A JP2003534405 A JP 2003534405A JP 2005508352 A5 JP2005508352 A5 JP 2005508352A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- cycloalkyl
- sulfonyl
- benzo
- thiazine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 125000000217 alkyl group Chemical group 0.000 claims 24
- 125000000753 cycloalkyl group Chemical group 0.000 claims 19
- 229910052739 hydrogen Inorganic materials 0.000 claims 18
- 239000001257 hydrogen Substances 0.000 claims 18
- UJVBZCCNLAAMOV-UHFFFAOYSA-N 2h-1,2-benzothiazine Chemical class C1=CC=C2C=CNSC2=C1 UJVBZCCNLAAMOV-UHFFFAOYSA-N 0.000 claims 15
- 150000002431 hydrogen Chemical class 0.000 claims 11
- 125000003342 alkenyl group Chemical group 0.000 claims 10
- 125000000304 alkynyl group Chemical group 0.000 claims 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 10
- -1 hydroxy, amino Chemical group 0.000 claims 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 7
- 125000003545 alkoxy group Chemical group 0.000 claims 7
- 125000003118 aryl group Chemical group 0.000 claims 7
- 229910052736 halogen Inorganic materials 0.000 claims 7
- 150000002367 halogens Chemical class 0.000 claims 7
- 125000001072 heteroaryl group Chemical group 0.000 claims 7
- 125000000623 heterocyclic group Chemical group 0.000 claims 7
- 125000002950 monocyclic group Chemical group 0.000 claims 7
- 229920006395 saturated elastomer Polymers 0.000 claims 7
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 5
- 208000035475 disorder Diseases 0.000 claims 5
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims 4
- 125000002837 carbocyclic group Chemical group 0.000 claims 4
- 125000004432 carbon atom Chemical group C* 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 claims 4
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 4
- 208000024827 Alzheimer disease Diseases 0.000 claims 3
- 229910052799 carbon Inorganic materials 0.000 claims 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
- 125000003003 spiro group Chemical group 0.000 claims 3
- MESFXNGUDNODTJ-UHFFFAOYSA-N 2h-thiazine 1,1-dioxide Chemical compound O=S1(=O)NC=CC=C1 MESFXNGUDNODTJ-UHFFFAOYSA-N 0.000 claims 2
- 102000003678 AMPA Receptors Human genes 0.000 claims 2
- 108090000078 AMPA Receptors Proteins 0.000 claims 2
- 208000026139 Memory disease Diseases 0.000 claims 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 2
- 125000004429 atom Chemical group 0.000 claims 2
- 210000003169 central nervous system Anatomy 0.000 claims 2
- 230000006735 deficit Effects 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 2
- 125000005647 linker group Chemical group 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000004193 piperazinyl group Chemical group 0.000 claims 2
- 125000003386 piperidinyl group Chemical group 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 2
- FQUYSHZXSKYCSY-UHFFFAOYSA-N 1,4-diazepane Chemical group C1CNCCNC1 FQUYSHZXSKYCSY-UHFFFAOYSA-N 0.000 claims 1
- FEKTZBLJGQYRGO-UHFFFAOYSA-N 1-[(3-cyclopentyl-1,1-dioxo-3,4-dihydro-2h-1$l^{6},2-benzothiazin-7-yl)sulfonyl]-n,n-dimethylpiperidin-4-amine Chemical compound C1CC(N(C)C)CCN1S(=O)(=O)C1=CC=C(CC(NS2(=O)=O)C3CCCC3)C2=C1 FEKTZBLJGQYRGO-UHFFFAOYSA-N 0.000 claims 1
- NXNVXQVVROGKLQ-UHFFFAOYSA-N 1-[(3-cyclopentyl-6-methyl-1,1-dioxo-3,4-dihydro-2h-1$l^{6},2-benzothiazin-7-yl)sulfonyl]piperidin-4-ol Chemical compound CC1=CC=2CC(C3CCCC3)NS(=O)(=O)C=2C=C1S(=O)(=O)N1CCC(O)CC1 NXNVXQVVROGKLQ-UHFFFAOYSA-N 0.000 claims 1
- OMTIEEKLZYEANQ-UHFFFAOYSA-N 3-cyclohexyl-7-(4-methylpiperazin-1-yl)sulfonyl-3,4-dihydro-2h-1$l^{6},2-benzothiazine 1,1-dioxide Chemical compound C1CN(C)CCN1S(=O)(=O)C1=CC=C(CC(NS2(=O)=O)C3CCCCC3)C2=C1 OMTIEEKLZYEANQ-UHFFFAOYSA-N 0.000 claims 1
- IABGLVGRFSTTHD-UHFFFAOYSA-N 3-cyclohexyl-7-piperidin-1-ylsulfonyl-3,4-dihydro-2h-1$l^{6},2-benzothiazine 1,1-dioxide Chemical compound C=1C=C2CC(C3CCCCC3)NS(=O)(=O)C2=CC=1S(=O)(=O)N1CCCCC1 IABGLVGRFSTTHD-UHFFFAOYSA-N 0.000 claims 1
- KQAGZLQCEURCKJ-UHFFFAOYSA-N 3-cyclopentyl-6-methyl-7-(4-methylpiperazin-1-yl)sulfonyl-3,4-dihydro-2h-1$l^{6},2-benzothiazine 1,1-dioxide Chemical compound C1CN(C)CCN1S(=O)(=O)C(C(=C1)C)=CC2=C1CC(C1CCCC1)NS2(=O)=O KQAGZLQCEURCKJ-UHFFFAOYSA-N 0.000 claims 1
- HPONCVDFKJUAHI-UHFFFAOYSA-N 3-cyclopentyl-6-methyl-7-morpholin-4-ylsulfonyl-3,4-dihydro-2h-1$l^{6},2-benzothiazine 1,1-dioxide Chemical compound CC1=CC=2CC(C3CCCC3)NS(=O)(=O)C=2C=C1S(=O)(=O)N1CCOCC1 HPONCVDFKJUAHI-UHFFFAOYSA-N 0.000 claims 1
- IUNMOUYVVPFXOJ-UHFFFAOYSA-N 3-cyclopentyl-6-methyl-7-piperidin-1-ylsulfonyl-3,4-dihydro-2h-1$l^{6},2-benzothiazine 1,1-dioxide Chemical compound CC1=CC=2CC(C3CCCC3)NS(=O)(=O)C=2C=C1S(=O)(=O)N1CCCCC1 IUNMOUYVVPFXOJ-UHFFFAOYSA-N 0.000 claims 1
- QZBQVXXESPXFPZ-UHFFFAOYSA-N 3-cyclopentyl-7-(4-methylpiperazin-1-yl)sulfonyl-3,4-dihydro-2h-1$l^{6},2-benzothiazine 1,1-dioxide Chemical compound C1CN(C)CCN1S(=O)(=O)C1=CC=C(CC(NS2(=O)=O)C3CCCC3)C2=C1 QZBQVXXESPXFPZ-UHFFFAOYSA-N 0.000 claims 1
- OFFUHSXGWXMEBR-UHFFFAOYSA-N 3-cyclopentyl-7-morpholin-4-ylsulfonyl-3,4-dihydro-2h-1$l^{6},2-benzothiazine 1,1-dioxide Chemical compound C=1C=C2CC(C3CCCC3)NS(=O)(=O)C2=CC=1S(=O)(=O)N1CCOCC1 OFFUHSXGWXMEBR-UHFFFAOYSA-N 0.000 claims 1
- DKONITGDYUPUBA-UHFFFAOYSA-N 3-cyclopentyl-7-piperidin-1-ylsulfonyl-3,4-dihydro-2h-1$l^{6},2-benzothiazine 1,1-dioxide Chemical compound C=1C=C2CC(C3CCCC3)NS(=O)(=O)C2=CC=1S(=O)(=O)N1CCCCC1 DKONITGDYUPUBA-UHFFFAOYSA-N 0.000 claims 1
- 208000007848 Alcoholism Diseases 0.000 claims 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 1
- 206010003805 Autism Diseases 0.000 claims 1
- 208000020706 Autistic disease Diseases 0.000 claims 1
- 201000006474 Brain Ischemia Diseases 0.000 claims 1
- 206010008120 Cerebral ischaemia Diseases 0.000 claims 1
- 208000020358 Learning disease Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical group C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims 1
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical group C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims 1
- 206010039966 Senile dementia Diseases 0.000 claims 1
- 201000001880 Sexual dysfunction Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 230000032683 aging Effects 0.000 claims 1
- 201000007930 alcohol dependence Diseases 0.000 claims 1
- 230000000747 cardiac effect Effects 0.000 claims 1
- 206010008118 cerebral infarction Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 125000001188 haloalkyl group Chemical group 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 125000002632 imidazolidinyl group Chemical group 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 201000003723 learning disability Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 206010027175 memory impairment Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 125000002757 morpholinyl group Chemical group 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 239000002581 neurotoxin Substances 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 208000020016 psychiatric disease Diseases 0.000 claims 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 claims 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 231100000872 sexual dysfunction Toxicity 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 125000004434 sulfur atom Chemical group 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200101498 | 2001-10-10 | ||
| PCT/DK2002/000654 WO2003031422A1 (en) | 2001-10-10 | 2002-10-02 | Novel benzothiazine derivatives, their preparation and use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005508352A JP2005508352A (ja) | 2005-03-31 |
| JP2005508352A5 true JP2005508352A5 (cg-RX-API-DMAC10.html) | 2006-01-05 |
Family
ID=8160760
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003534405A Withdrawn JP2005508352A (ja) | 2001-10-10 | 2002-10-02 | 新規ベンゾチアジン誘導体、その製造方法及びその使用方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US7199118B2 (cg-RX-API-DMAC10.html) |
| EP (1) | EP1436270A1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2005508352A (cg-RX-API-DMAC10.html) |
| CN (1) | CN1275951C (cg-RX-API-DMAC10.html) |
| CA (1) | CA2458388A1 (cg-RX-API-DMAC10.html) |
| MX (1) | MXPA04003297A (cg-RX-API-DMAC10.html) |
| NZ (1) | NZ531511A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2003031422A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3547859B2 (ja) * | 1995-07-14 | 2004-07-28 | 愛知機械工業株式会社 | ２方向差動クラッチ |
| FR2856064B1 (fr) * | 2003-06-13 | 2005-08-19 | Servier Lab | Nouveaux derives de benzothiazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
| FR2879201B1 (fr) * | 2004-12-10 | 2007-02-16 | Servier Lab | Nouveaux derives de benzothiazine et benzothiadiazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| FR2933698A1 (fr) * | 2008-07-09 | 2010-01-15 | Servier Lab | Nouveaux derives de benzothiadiazines cycloalkylees, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
| FR2955107B1 (fr) * | 2010-01-08 | 2012-03-02 | Servier Lab | Nouveaux derives thiochromanes, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| WO2012020848A1 (en) * | 2010-08-10 | 2012-02-16 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and use thereof |
| TWI873185B (zh) | 2019-09-16 | 2025-02-21 | 日商武田藥品工業股份有限公司 | 唑稠合之嗒-3(2h)-酮衍生物 |
| CN111393385B (zh) * | 2020-04-15 | 2022-01-18 | 华南理工大学 | 一种苯并噻嗪甲醛衍生物的合成方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3113075A (en) * | 1960-10-17 | 1963-12-03 | Merck & Co Inc | Heterocyclic compounds |
| DE1302858B (cg-RX-API-DMAC10.html) * | 1962-09-21 | 1972-05-04 | ||
| FR1552763A (cg-RX-API-DMAC10.html) * | 1963-11-08 | 1969-01-10 | ||
| FR3136M (fr) | 1963-11-08 | 1965-02-15 | Merck & Co Inc | Nouveaux médicaments diurétiques. |
| RU2214405C2 (ru) | 1998-02-18 | 2003-10-20 | НьюроСёрч А/С | Новые соединения и их применение в качестве положительных модуляторов амра-рецепторов |
| DE10004572A1 (de) | 2000-02-02 | 2001-08-09 | Boehringer Ingelheim Pharma | Neue positive allosterische AMPA-Rezeptor Modulatoren (PAARM), Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel |
-
2002
- 2002-10-02 NZ NZ531511A patent/NZ531511A/en unknown
- 2002-10-02 US US10/489,640 patent/US7199118B2/en not_active Expired - Fee Related
- 2002-10-02 MX MXPA04003297A patent/MXPA04003297A/es unknown
- 2002-10-02 CA CA002458388A patent/CA2458388A1/en not_active Abandoned
- 2002-10-02 EP EP02800544A patent/EP1436270A1/en not_active Withdrawn
- 2002-10-02 JP JP2003534405A patent/JP2005508352A/ja not_active Withdrawn
- 2002-10-02 CN CNB028195248A patent/CN1275951C/zh not_active Expired - Fee Related
- 2002-10-02 WO PCT/DK2002/000654 patent/WO2003031422A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2155707B1 (en) | Metabolites of carbamoyl-cyclohexane derivatives | |
| JP2983296B2 (ja) | 新規なｎ−アミノアルキルフルオレンカルボキサミド；新規な種類のドーパミンリセプタ亜型特異性リガンド | |
| EP3768669B1 (en) | Piperazine azaspiro derivaves | |
| IL271290B2 (en) | Dihydro-pyrrolo-pyridine derivatives | |
| EP3126361B1 (en) | Chromene and 1,1a,2,7b-tetrahydrocyclopropa[c]chromene pyridopyrazinediones as gamma-secretase modulators | |
| NO20071967L (no) | Imidazo-benzodiazepinderivater | |
| RU2007105350A (ru) | 3-(гетероарилокси)-2-алкил-1-азабициклоалкильные производные, как лиганды альфа-7-nachr (никотиновых ацетилхолиновых рецепторов), предназначенные для лечения заболеваний центральной нервной системы | |
| JP2023553094A5 (cg-RX-API-DMAC10.html) | ||
| RU2002115862A (ru) | Производные спиро(2h-1-бензопиран-2,4'-пиперидина) как ингибиторы транспорта глицина | |
| JP2020520925A (ja) | 化合物、組成物および方法 | |
| TW200734328A (en) | Aryl-isoxazolo-4-yl-imidazo [1,5-a] pyridine derivatives | |
| ES2742078T3 (es) | Piridonas bicíclicas novedosas como moduladores de gamma-secretasa | |
| JP2024544533A (ja) | Ｒｉｐｋ１阻害剤としてのイソオキサゾリジン及びその使用 | |
| CN120641414A (zh) | 经取代的四氢吡咯并-吡啶酮化合物及其在治疗医学病状中的用途 | |
| ATE402707T1 (de) | Imidazoä1,5aütriazoloä1,5dübenzodiazepin- derivative zur behandlung kognitiver störungen | |
| TW200631953A (en) | Tetracyclic imidazo-benzodiazepines | |
| WO2011000945A9 (en) | Aminoalkamides for use in the treatment of inflammatory, degenerative or demyelinating diseases of the cns | |
| RU2005101345A (ru) | Новые тетрациклические арилкарбонилиндолы с аффинностью к серотониновым рецепторам, пригодные в качестве лекарственных средств, способ их получения и фармацевтические композиции на их основе | |
| AU2017321416B2 (en) | Hydroxynorketamine derivatives for the treatment of disorders | |
| RU2008102154A (ru) | ЗАМЕЩЕННЫЕ 4-СУЛЬФОНИЛ-ПИРАЗОЛЫ И 3-СУЛЬФОНИЛ-ПИРАЗОЛО[1,5-a]ПИРИМИДИНЫ-АНТАГОНИСТЫ СЕРОТОНИНОВЫХ 5-НТ6 РЕЦЕПТОРОВ, ЛЕКАРСТВЕННАЯ СУБСТАНЦИЯ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, ЛЕКАРСТВЕННЫЙ ПРЕПАРАТ И СПОСОБЫ ИХ ПОЛУЧЕНИЯ | |
| HK40099374A (en) | Piperazine azaspiro derivatives | |
| EP3414253A1 (en) | C5-c6-oxacylic fused iminothiazine dioxide compounds bearing an ether linker as bace inhibitors, compositions, and their use | |
| EA052086B1 (ru) | Антагонисты рецептора гистамина h3 и их фармацевтическое применение | |
| JP2025517627A (ja) | 神経変性障害の治療のためのスルホンアミド化合物及びその薬学的組成物 | |
| HK40045213B (en) | Piperazine azaspiro derivaves |